{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T03:44:51Z","timestamp":1785901491473,"version":"3.56.0"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T00:00:00Z","timestamp":1698364800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T00:00:00Z","timestamp":1698364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Allergy Asthma Rep"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s11882-023-01112-y","type":"journal-article","created":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T09:03:12Z","timestamp":1698397392000},"page":"647-654","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Neuromyelitis Optica: Pathogenesis Overlap with Other Autoimmune Diseases"],"prefix":"10.1007","volume":"23","author":[{"given":"Nadim","family":"Taheri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Sarrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad S.","family":"Soyfoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,27]]},"reference":[{"issue":"6","key":"1112_CR1","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11926-021-01000-2","volume":"23","author":"RA Cruz","year":"2021","unstructured":"Cruz RA, Chaudhary S, Guevara M, Meltzer E. Neuromyelitis optica spectrum disorders (NMOSD) and connective tissue disease (CTD): an update for the rheumatologist. Curr Rheumatol Rep. 2021;23(6):33.","journal-title":"Curr Rheumatol Rep"},{"issue":"2","key":"1112_CR2","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177\u201389.","journal-title":"Neurology"},{"issue":"7","key":"1112_CR3","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1056\/NEJMra1904655","volume":"387","author":"DM Wingerchuk","year":"2022","unstructured":"Wingerchuk DM, Lucchinetti CF. Neuromyelitis optica spectrum disorder. N Engl J Med. 2022;387(7):631\u20139.","journal-title":"N Engl J Med"},{"key":"1112_CR4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1742-2094-10-8","volume":"10","author":"S Jarius","year":"2013","unstructured":"Jarius S, Wildemann B. The history of neuromyelitis optica. J Neuroinflammation. 2013;10:8.","journal-title":"J Neuroinflammation"},{"issue":"9451","key":"1112_CR5","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","volume":"364","author":"VA Lennon","year":"2004","unstructured":"Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364(9451):2106\u201312.","journal-title":"Lancet"},{"key":"1112_CR6","doi-asserted-by":"crossref","unstructured":"\u2022 Pruss H. Autoantibodies in neurological disease. Nat Rev Immunol. 2021;21(12):798\u2013813. Article describing the inherent pathological mechanisms underlying NMO.","DOI":"10.1038\/s41577-021-00543-w"},{"issue":"3","key":"1112_CR7","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","volume":"22","author":"B Banwell","year":"2023","unstructured":"Banwell B, Bennett JL, Marignier R, Kim HJ, Brilot F, Flanagan EP, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol. 2023;22(3):268\u201382.","journal-title":"Lancet Neurol"},{"issue":"7","key":"1112_CR8","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1177\/1756285617709723","volume":"10","author":"SM Kim","year":"2017","unstructured":"Kim SM, Kim SJ, Lee HJ, Kuroda H, Palace J, Fujihara K. Differential diagnosis of neuromyelitis optica spectrum disorders. Ther Adv Neurol Disord. 2017;10(7):265\u201389.","journal-title":"Ther Adv Neurol Disord"},{"key":"1112_CR9","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.msard.2018.11.008","volume":"27","author":"S Shahmohammadi","year":"2019","unstructured":"Shahmohammadi S, Doosti R, Shahmohammadi A, Mohammadianinejad SE, Sahraian MA, Azimi AR, et al. Autoimmune diseases associated with Neuromyelitis Optica Spectrum Disorders: a literature review. Mult Scler Relat Disord. 2019;27:350\u201363.","journal-title":"Mult Scler Relat Disord"},{"key":"1112_CR10","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3389\/fneur.2020.00501","volume":"11","author":"JY Hor","year":"2020","unstructured":"Hor JY, Asgari N, Nakashima I, Broadley SA, Leite MI, Kissani N, et al. Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide. Front Neurol. 2020;11:501.","journal-title":"Front Neurol"},{"issue":"2","key":"1112_CR11","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1212\/WNL.0000000000011153","volume":"96","author":"V Papp","year":"2021","unstructured":"Papp V, Magyari M, Aktas O, Berger T, Broadley SA, Cabre P, et al. Worldwide incidence and prevalence of neuromyelitis optica: a systematic review. Neurology. 2021;96(2):59\u201377.","journal-title":"Neurology"},{"issue":"10","key":"1112_CR12","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1136\/jnnp-2017-315998","volume":"88","author":"JW Hyun","year":"2017","unstructured":"Hyun JW, Woodhall MR, Kim SH, Jeong IH, Kong B, Kim G, et al. Longitudinal analysis of myelin oligodendrocyte glycoprotein antibodies in CNS inflammatory diseases. J Neurol Neurosurg Psychiatry. 2017;88(10):811\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9","key":"1112_CR13","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1002\/acn3.51642","volume":"9","author":"KH Kim","year":"2022","unstructured":"Kim KH, Kim SH, Hyun JW, Kim Y, Park H, Kim HJ. Seroprevalence of anti-myelin oligodendrocyte glycoprotein antibodies in adults with myelitis. Ann Clin Transl Neurol. 2022;9(9):1481\u20136.","journal-title":"Ann Clin Transl Neurol"},{"issue":"4","key":"1112_CR14","first-page":"205521732211281","volume":"8","author":"N Molazadeh","year":"2022","unstructured":"Molazadeh N, Bose G, Lotan I, Levy M. Autoimmune diseases and cancers overlapping with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a systematic review. Mult Scler J Exp Transl Clin. 2022;8(4):20552173221128170.","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"2","key":"1112_CR15","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s13760-018-0900-5","volume":"118","author":"S Eskandarieh","year":"2018","unstructured":"Eskandarieh S, Nedjat S, Abdollahpour I, Azimi AR, Moghadasi AN, Asgari N, et al. Environmental risk factors in neuromyelitis optica spectrum disorder: a case-control study. Acta Neurol Belg. 2018;118(2):277\u201387.","journal-title":"Acta Neurol Belg"},{"issue":"1","key":"1112_CR16","doi-asserted-by":"publisher","first-page":"21312","DOI":"10.1038\/s41598-022-21592-8","volume":"12","author":"H Stiebel-Kalish","year":"2022","unstructured":"Stiebel-Kalish H, Rubarth K, Shouchane-Blum K, Tiosano A, Lotan I, Hellmann MA, et al. Obesity is associated with myelin oligodendrocyte glycoprotein antibody-associated disease in acute optic neuritis. Sci Rep. 2022;12(1):21312.","journal-title":"Sci Rep"},{"issue":"9","key":"1112_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.1350","volume":"9","author":"X Chen","year":"2019","unstructured":"Chen X, Fan R, Peng F, Liu J, Huang J, Chen Z, et al. Blood pressure and body fat percent in women with NMOSD. Brain Behav. 2019;9(9): e01350.","journal-title":"Brain Behav"},{"issue":"12","key":"1112_CR18","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1177\/13524585221096964","volume":"28","author":"EB Cho","year":"2022","unstructured":"Cho EB, Yeo Y, Jung JH, Jeong SM, Han K, Yang JH, et al. Acute myocardial infarction risk in multiple sclerosis and neuromyelitis optica spectrum disorder: a nationwide cohort study in South Korea. Mult Scler. 2022;28(12):1849\u201358.","journal-title":"Mult Scler"},{"key":"1112_CR19","doi-asserted-by":"crossref","unstructured":"Alvarenga MP, do Carmo LF, Vasconcelos CCF, Alvarenga MP, Alvarenga-Filho H, de Melo Bento CA, et al. Neuromyelitis optica is an HLA associated disease different from Multiple Sclerosis: a systematic review with meta-analysis. Sci Rep. 2021;11(1):152.","DOI":"10.1038\/s41598-020-80535-3"},{"issue":"11","key":"1112_CR20","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1002\/acn3.51147","volume":"7","author":"T Matsushita","year":"2020","unstructured":"Matsushita T, Masaki K, Isobe N, Sato S, Yamamoto K, Nakamura Y, et al. Genetic factors for susceptibility to and manifestations of neuromyelitis optica. Ann Clin Transl Neurol. 2020;7(11):2082\u201393.","journal-title":"Ann Clin Transl Neurol"},{"issue":"5","key":"1112_CR21","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.ajhg.2012.08.026","volume":"91","author":"DL Morris","year":"2012","unstructured":"Morris DL, Taylor KE, Fernando MM, Nititham J, Alarcon-Riquelme ME, Barcellos LF, et al. Unraveling multiple MHC gene associations with systemic lupus erythematosus: model choice indicates a role for HLA alleles and non-HLA genes in Europeans. Am J Hum Genet. 2012;91(5):778\u201393.","journal-title":"Am J Hum Genet"},{"key":"1112_CR22","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202(4):473\u20137.\u00a0Role of aquaporin-4 in multiple sclerosis.","DOI":"10.1084\/jem.20050304"},{"key":"1112_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.112384","volume":"145","author":"QL Pan","year":"2022","unstructured":"Pan QL, Lin FX, Liu N, Chen RC. The role of aquaporin 4 (AQP4) in spinal cord injury. Biomed Pharmacother. 2022;145: 112384.","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"1112_CR24","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/nan.12574","volume":"46","author":"VTW Chang","year":"2020","unstructured":"Chang VTW, Chang HM. Review: Recent advances in the understanding of the pathophysiology of neuromyelitis optica spectrum disorder. Neuropathol Appl Neurobiol. 2020;46(3):199\u2013218.","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"12","key":"1112_CR25","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/s41583-019-0233-2","volume":"20","author":"JJ Sabatino Jr","year":"2019","unstructured":"Sabatino JJ Jr, Probstel AK, Zamvil SS. B cells in autoimmune and neurodegenerative central nervous system diseases. Nat Rev Neurosci. 2019;20(12):728\u201345.","journal-title":"Nat Rev Neurosci"},{"key":"1112_CR26","doi-asserted-by":"crossref","unstructured":"Maciak K, Pietrasik S, Dziedzic A, Redlicka J, Saluk-Bijak J, Bijak M, et al. Th17-related cytokines as potential discriminatory markers between neuromyelitis optica (Devic\u2019s disease) and Multiple Sclerosis-A Review. Int J Mol Sci. 2021;22(16).","DOI":"10.3390\/ijms22168946"},{"issue":"1","key":"1112_CR27","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41572-020-0214-9","volume":"6","author":"S Jarius","year":"2020","unstructured":"Jarius S, Paul F, Weinshenker BG, Levy M, Kim HJ, Wildemann B. Neuromyelitis optica Nat Rev Dis Primers. 2020;6(1):85.","journal-title":"Neuromyelitis optica Nat Rev Dis Primers"},{"issue":"13","key":"1112_CR28","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1177\/1352458515571446","volume":"21","author":"S Saadoun","year":"2015","unstructured":"Saadoun S, Papadopoulos MC. Role of membrane complement regulators in neuromyelitis optica. Mult Scler. 2015;21(13):1644\u201354.","journal-title":"Mult Scler"},{"issue":"2","key":"1112_CR29","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.brainresrev.2004.01.003","volume":"45","author":"P Vourc'h","year":"2004","unstructured":"Vourc\u2019h P, Andres C. Oligodendrocyte myelin glycoprotein (OMgp): evolution, structure and function. Brain Res Brain Res Rev. 2004;45(2):115\u201324.","journal-title":"Brain Res Brain Res Rev"},{"key":"1112_CR30","doi-asserted-by":"crossref","unstructured":"Ambrosius W, Michalak S, Kozubski W, Kalinowska A. Myelin Oligodendrocyte glycoprotein antibody-associated disease: current insights into the disease pathophysiology, diagnosis and management. Int J Mol Sci. 2020;22(1).","DOI":"10.3390\/ijms22010100"},{"issue":"5","key":"1112_CR31","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1093\/brain\/awaa102","volume":"143","author":"Y Takai","year":"2020","unstructured":"Takai Y, Misu T, Kaneko K, Chihara N, Narikawa K, Tsuchida S, et al. Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study. Brain. 2020;143(5):1431\u201346.","journal-title":"Brain"},{"key":"1112_CR32","unstructured":"Devic E. My\u00e9lite aigu\u00eb dorso-lombaire avec n\u00e9vrite optique.-Autopsie. Congr\u00e8s fran\u00e7ais de m\u00e9decine. 1895;434\u20139."},{"issue":"6","key":"1112_CR33","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.survophthal.2019.06.001","volume":"64","author":"A Abel","year":"2019","unstructured":"Abel A, McClelland C, Lee MS. Critical review: typical and atypical optic neuritis. Surv Ophthalmol. 2019;64(6):770\u20139.","journal-title":"Surv Ophthalmol"},{"key":"1112_CR34","doi-asserted-by":"crossref","unstructured":"Lucas S, Lalive PH, Lascano AM. Paroxysmal painful tonic spasms in neuromyelitis optica spectrum disorder. eNeurologicalSci. 2023;30:100443.","DOI":"10.1016\/j.ensci.2023.100443"},{"issue":"6","key":"1112_CR35","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1177\/1352458516665497","volume":"23","author":"M Netravathi","year":"2017","unstructured":"Netravathi M, Saini J, Mahadevan A, Hari-Krishna B, Yadav R, Pal PK, et al. Is pruritus an indicator of aquaporin-positive neuromyelitis optica? Mult Scler. 2017;23(6):810\u20137.","journal-title":"Mult Scler"},{"issue":"3","key":"1112_CR36","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1177\/1352458518813105","volume":"25","author":"CR Camara-Lemarroy","year":"2019","unstructured":"Camara-Lemarroy CR, Burton JM. Area postrema syndrome: a short history of a pearl in demyelinating diseases. Mult Scler. 2019;25(3):325\u20139.","journal-title":"Mult Scler"},{"issue":"7","key":"1112_CR37","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1177\/1352458513507822","volume":"20","author":"L Kremer","year":"2014","unstructured":"Kremer L, Mealy M, Jacob A, Nakashima I, Cabre P, Bigi S, et al. Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients. Mult Scler. 2014;20(7):843\u20137.","journal-title":"Mult Scler"},{"key":"1112_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.101869","volume":"38","author":"Y Beigneux","year":"2020","unstructured":"Beigneux Y, Arnulf I, Guillaume-Jugnot P, Leu-Semenescu S, Maillart E, Lubetzki C, et al. Secondary hypersomnia as an initial manifestation of neuromyelitis optica spectrum disorders. Mult Scler Relat Disord. 2020;38: 101869.","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"1112_CR39","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s13760-021-01792-1","volume":"122","author":"M Etemadifar","year":"2022","unstructured":"Etemadifar M, Nouri H, Khorvash R, Salari M, Ghafari K, Aghababaee A. Frequency of diencephalic syndrome in NMOSD. Acta Neurol Belg. 2022;122(4):961\u20137.","journal-title":"Acta Neurol Belg"},{"issue":"7","key":"1112_CR40","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1177\/1352458515572406","volume":"21","author":"L Pandit","year":"2015","unstructured":"Pandit L, Asgari N, Apiwattanakul M, Palace J, Paul F, Leite MI, et al. Demographic and clinical features of neuromyelitis optica: a review. Mult Scler. 2015;21(7):845\u201353.","journal-title":"Mult Scler"},{"issue":"22","key":"1112_CR41","doi-asserted-by":"publisher","first-page":"e2089","DOI":"10.1212\/WNL.0000000000006574","volume":"91","author":"SH Kim","year":"2018","unstructured":"Kim SH, Mealy MA, Levy M, Schmidt F, Ruprecht K, Paul F, et al. Racial differences in neuromyelitis optica spectrum disorder. Neurology. 2018;91(22):e2089\u201399.","journal-title":"Neurology"},{"issue":"3","key":"1112_CR42","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000231","volume":"3","author":"M Majed","year":"2016","unstructured":"Majed M, Fryer JP, McKeon A, Lennon VA, Pittock SJ. Clinical utility of testing AQP4-IgG in CSF: guidance for physicians. Neurol Neuroimmunol Neuroinflamm. 2016;3(3): e231.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"1112_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104414","volume":"69","author":"N Masha","year":"2023","unstructured":"Masha N, Kimbrough DJ, Eckstein CP, Hudak NM, Skeen MB, Hartsell FL, et al. Neuromyelitis optica: clinical course and potential prognostic indicators. Mult Scler Relat Disord. 2023;69: 104414.","journal-title":"Mult Scler Relat Disord"},{"issue":"9","key":"1112_CR44","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","volume":"6","author":"DM Wingerchuk","year":"2007","unstructured":"Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6(9):805\u201315.","journal-title":"Lancet Neurol"},{"issue":"12","key":"1112_CR45","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s11910-019-1014-z","volume":"19","author":"DA Tajfirouz","year":"2019","unstructured":"Tajfirouz DA, Bhatti MT, Chen JJ. Clinical characteristics and treatment of MOG-IgG-associated optic neuritis. Curr Neurol Neurosci Rep. 2019;19(12):100.","journal-title":"Curr Neurol Neurosci Rep"},{"key":"1112_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2021.577494","volume":"353","author":"Q Du","year":"2021","unstructured":"Du Q, Shi Z, Chen H, Zhang Y, Wang J, Qiu Y, et al. Comparison of clinical characteristics and prognoses in patients with different AQP4-Ab and MOG-Ab serostatus with neuromyelitis optica spectrum disorders. J Neuroimmunol. 2021;353: 577494.","journal-title":"J Neuroimmunol"},{"issue":"3","key":"1112_CR47","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3109\/08916934.2014.883501","volume":"47","author":"A Iyer","year":"2014","unstructured":"Iyer A, Elsone L, Appleton R, Jacob A. A review of the current literature and a guide to the early diagnosis of autoimmune disorders associated with neuromyelitis optica. Autoimmunity. 2014;47(3):154\u201361.","journal-title":"Autoimmunity"},{"issue":"1","key":"1112_CR48","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1001\/archneurol.2007.17","volume":"65","author":"SJ Pittock","year":"2008","unstructured":"Pittock SJ, Lennon VA, de Seze J, Vermersch P, Homburger HA, Wingerchuk DM, et al. Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol. 2008;65(1):78\u201383.","journal-title":"Arch Neurol"},{"key":"1112_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.959469","volume":"13","author":"X Wang","year":"2022","unstructured":"Wang X, Shi Z, Zhao Z, Chen H, Lang Y, Kong L, et al. The causal relationship between neuromyelitis optica spectrum disorder and other autoimmune diseases. Front Immunol. 2022;13: 959469.","journal-title":"Front Immunol"},{"key":"1112_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2021.577699","volume":"360","author":"F Pache","year":"2021","unstructured":"Pache F, Ringelstein M, Aktas O, Kleiter I, Jarius S, Siebert N, et al. C3 and C4 complement levels in AQP4-IgG-positive NMOSD and in MOGAD. J Neuroimmunol. 2021;360: 577699.","journal-title":"J Neuroimmunol"},{"issue":"1","key":"1112_CR51","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/1352458511431077","volume":"18","author":"DM Wingerchuk","year":"2012","unstructured":"Wingerchuk DM, Weinshenker BG. The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease. Mult Scler. 2012;18(1):5\u201310.","journal-title":"Mult Scler"},{"key":"1112_CR52","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12883-014-0162-7","volume":"14","author":"B Zhang","year":"2014","unstructured":"Zhang B, Zhong Y, Wang Y, Dai Y, Qiu W, Zhang L, et al. Neuromyelitis optica spectrum disorders without and with autoimmune diseases. BMC Neurol. 2014;14:162.","journal-title":"BMC Neurol"},{"issue":"5","key":"1112_CR53","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1007\/s10072-023-06611-4","volume":"44","author":"E Carnero Contentti","year":"2023","unstructured":"Carnero Contentti E, Lopez PA, Pettinicchi JP, Tkachuk V, Daccach Marques V, de Castillo IS, et al. Neuromyelitis optica spectrum disorders with and without associated autoimmune diseases. Neurol Sci. 2023;44(5):1731\u20137.","journal-title":"Neurol Sci"},{"key":"1112_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2022.120460","volume":"443","author":"MR Alvarez","year":"2022","unstructured":"Alvarez MR, Gurung A, Velayndhan V, Cuascut F, Alkabie S, Freeman L, et al. Predictors of overlapping autoimmune disease in Neuromyelitis Optica Spectrum disorder (NMOSD): a retrospective analysis in two inner-city hospitals. J Neurol Sci. 2022;443: 120460.","journal-title":"J Neurol Sci"},{"issue":"9","key":"1112_CR55","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1002\/art.40930","volume":"71","author":"M Aringer","year":"2019","unstructured":"Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European league against rheumatism\/american college of rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol. 2019;71(9):1400\u201312.","journal-title":"Arthritis Rheumatol"},{"key":"1112_CR56","doi-asserted-by":"crossref","unstructured":"The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999;42(4):599\u2013608.","DOI":"10.1002\/1529-0131(199904)42:4<599::AID-ANR2>3.0.CO;2-F"},{"issue":"14","key":"1112_CR57","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1177\/0961203319886103","volume":"28","author":"JN Williams","year":"2019","unstructured":"Williams JN, Speyer CB, Kreps DJ, Kimbrough DJ, Costenbader K, Bhattacharyya S. Spinal cord syndromes in patients with systemic lupus erythematosus: differentiating lupus myelitis, neuromyelitis optica, and multiple sclerosis. Lupus. 2019;28(14):1656\u201362.","journal-title":"Lupus"},{"key":"1112_CR58","doi-asserted-by":"crossref","unstructured":"Tavor Y, Herskovitz M, Ronen G, Balbir-Gurman A. Longitudinally extensive transverse myelitis in a lupus-neuromyelitis optica overlap. Rambam Maimonides Med J. 2021;12(1).","DOI":"10.5041\/RMMJ.10429"},{"issue":"3","key":"1112_CR59","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1177\/1352458517699791","volume":"24","author":"N Asgari","year":"2018","unstructured":"Asgari N, Jarius S, Laustrup H, Skejoe HP, Lillevang ST, Weinshenker BG, et al. Aquaporin-4-autoimmunity in patients with systemic lupus erythematosus: a predominantly population-based study. Mult Scler. 2018;24(3):331\u20139.","journal-title":"Mult Scler"},{"issue":"4","key":"1112_CR60","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1177\/0961203320905668","volume":"29","author":"S Zhang","year":"2020","unstructured":"Zhang S, Wang Z, Zhao J, Wu DI, Li J, Wang Q, et al. Clinical features of transverse myelitis associated with systemic lupus erythematosus. Lupus. 2020;29(4):389\u201397.","journal-title":"Lupus"},{"key":"1112_CR61","first-page":"8820071","volume":"2020","author":"MGS Ochi","year":"2020","unstructured":"Ochi MGS, Shapiro SC, Melamed E. Lupus and NMOSD: the blending of humoral autoimmunity. Case Rep Rheumatol. 2020;2020:8820071.","journal-title":"Case Rep Rheumatol"},{"issue":"1","key":"1112_CR62","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/art.39859","volume":"69","author":"CH Shiboski","year":"2017","unstructured":"Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, et al. 2016 American College of Rheumatology\/European League against rheumatism classification criteria for primary sjogren\u2019s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol. 2017;69(1):35\u201345.","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"1112_CR63","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1590\/0004-282X20140097","volume":"72","author":"DC Carvalho","year":"2014","unstructured":"Carvalho DC, Tironi TS, Freitas DS, Kleinpaul R, Talim NC, Lana-Peixoto MA. Sjogren syndrome and neuromyelitis optica spectrum disorder co-exist in a common autoimmune milieu. Arq Neuropsiquiatr. 2014;72(8):619\u201324.","journal-title":"Arq Neuropsiquiatr"},{"issue":"1","key":"1112_CR64","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s10067-005-1137-2","volume":"25","author":"AG Tristano","year":"2006","unstructured":"Tristano AG. A case of Sjogren\u2019s syndrome with acute transverse myelitis and polyneuropathy in a patient free of sicca symptoms. Clin Rheumatol. 2006;25(1):113\u20134.","journal-title":"Clin Rheumatol"},{"issue":"2","key":"1112_CR65","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/S0022-510X(00)00334-8","volume":"176","author":"Y Manabe","year":"2000","unstructured":"Manabe Y, Sasaki C, Warita H, Hayashi T, Shiro Y, Sakai K, et al. Sjogren\u2019s syndrome with acute transverse myelopathy as the initial manifestation. J Neurol Sci. 2000;176(2):158\u201361.","journal-title":"J Neurol Sci"},{"issue":"4","key":"1112_CR66","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.semarthrit.2010.05.005","volume":"40","author":"JM Kahlenberg","year":"2011","unstructured":"Kahlenberg JM. Neuromyelitis optica spectrum disorder as an initial presentation of primary Sjogren\u2019s syndrome. Semin Arthritis Rheum. 2011;40(4):343\u20138.","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"1112_CR67","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1007\/s00415-020-10377-6","volume":"268","author":"T Akaishi","year":"2021","unstructured":"Akaishi T, Takahashi T, Fujihara K, Misu T, Fujimori J, Takai Y, et al. Impact of comorbid Sjogren syndrome in anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders. J Neurol. 2021;268(5):1938\u201344.","journal-title":"J Neurol"},{"key":"1112_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103494","volume":"58","author":"L Lin","year":"2022","unstructured":"Lin L, Hang H, Zhang J, Lu J, Chen D, Shi J. Clinical significance of anti-SSA\/Ro antibody in neuromyelitis optica spectrum disorders. Mult Scler Relat Disord. 2022;58: 103494.","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"1112_CR69","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G, Benatar M, Cea G, Evoli A, et al. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology. 2021;96(3):114\u201322.","journal-title":"Neurology"},{"issue":"1\u20132","key":"1112_CR70","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jns.2009.08.040","volume":"287","author":"A Uzawa","year":"2009","unstructured":"Uzawa A, Mori M, Iwai Y, Kobayashi M, Hayakawa S, Kawaguchi N, et al. Association of anti-aquaporin-4 antibody-positive neuromyelitis optica with myasthenia gravis. J Neurol Sci. 2009;287(1\u20132):105\u20137.","journal-title":"J Neurol Sci"},{"issue":"20","key":"1112_CR71","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1212\/WNL.0b013e31825644ff","volume":"78","author":"MI Leite","year":"2012","unstructured":"Leite MI, Coutinho E, Lana-Peixoto M, Apostolos S, Waters P, Sato D, et al. Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients. Neurology. 2012;78(20):1601\u20137.","journal-title":"Neurology"},{"key":"1112_CR72","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.3389\/fimmu.2017.01785","volume":"8","author":"Z Wang","year":"2017","unstructured":"Wang Z, Yan Y. Immunopathogenesis in myasthenia gravis and neuromyelitis optica. Front Immunol. 2017;8:1785.","journal-title":"Front Immunol"},{"issue":"2","key":"1112_CR73","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1017\/cjn.2021.508","volume":"50","author":"D Dodig","year":"2023","unstructured":"Dodig D, Genge A, Selchen D, Freedman MS. Complement inhibition in myasthenia gravis and neuromyelitis optica spectrum disorder. Can J Neurol Sci. 2023;50(2):165\u201373.","journal-title":"Can J Neurol Sci"},{"issue":"3","key":"1112_CR74","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s13311-022-01223-w","volume":"19","author":"JA McCombe","year":"2022","unstructured":"McCombe JA, Pittock SJ. Anti-complement agents for autoimmune neurological disease. Neurotherapeutics. 2022;19(3):711\u201328.","journal-title":"Neurotherapeutics"},{"issue":"3","key":"1112_CR75","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1006\/clin.1997.4412","volume":"84","author":"DL Jacobson","year":"1997","unstructured":"Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol. 1997;84(3):223\u201343.","journal-title":"Clin Immunol Immunopathol"},{"issue":"12","key":"1112_CR76","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1136\/jnnp-2011-300403","volume":"82","author":"A Nagaishi","year":"2011","unstructured":"Nagaishi A, Takagi M, Umemura A, Tanaka M, Kitagawa Y, Matsui M, et al. Clinical features of neuromyelitis optica in a large Japanese cohort: comparison between phenotypes. J Neurol Neurosurg Psychiatry. 2011;82(12):1360\u20134.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1112_CR77","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jneuroim.2015.02.014","volume":"281","author":"H Li","year":"2015","unstructured":"Li H, Dai Y, Wu AM, Sun X, Lin Y, Lv K, et al. Anti-thyroid antibodies and cerebrospinal fluid findings in neuromyelitis optica spectrum disorders. J Neuroimmunol. 2015;281:38\u201343.","journal-title":"J Neuroimmunol"},{"key":"1112_CR78","doi-asserted-by":"crossref","unstructured":"Jarius S, Aktas O, Ayzenberg I, Bellmann-Strobl J, Berthele A, Giglhuber K, et al. Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis. J Neurol. 2023;270(7):3341\u201368.","DOI":"10.1007\/s00415-023-11634-0"},{"key":"1112_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.102750","volume":"49","author":"Y Takai","year":"2021","unstructured":"Takai Y, Kuroda H, Misu T, Akaishi T, Nakashima I, Takahashi T, et al. Optimal management of neuromyelitis optica spectrum disorder with aquaporin-4 antibody by oral prednisolone maintenance therapy. Mult Scler Relat Disord. 2021;49: 102750.","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"1112_CR80","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12974-022-02420-2","volume":"19","author":"S Demuth","year":"2022","unstructured":"Demuth S, Guillaume M, Bourre B, Ciron J, Zephir H, Sirejacob Y, et al. Treatment regimens for neuromyelitis optica spectrum disorder attacks: a retrospective cohort study. J Neuroinflammation. 2022;19(1):62.","journal-title":"J Neuroinflammation"},{"issue":"4","key":"1112_CR81","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1177\/1352458513495938","volume":"20","author":"L Elsone","year":"2014","unstructured":"Elsone L, Panicker J, Mutch K, Boggild M, Appleton R, Jacob A. Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients. Mult Scler. 2014;20(4):501\u20134.","journal-title":"Mult Scler"},{"issue":"9","key":"1112_CR82","doi-asserted-by":"publisher","first-page":"3857","DOI":"10.1007\/s10072-021-05079-4","volume":"42","author":"J Lin","year":"2021","unstructured":"Lin J, Xue B, Zhu R, Pan J, Li J, Lin Y, et al. Intravenous immunoglobulin as the rescue treatment in NMOSD patients. Neurol Sci. 2021;42(9):3857\u201363.","journal-title":"Neurol Sci"},{"key":"1112_CR83","doi-asserted-by":"crossref","unstructured":"Tahara M, Oeda T, Okada K, Kiriyama T, Ochi K, Maruyama H, et al. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2020;19(4):298\u2013306. (Treatment of NMO with rituximab).","DOI":"10.1016\/S1474-4422(20)30066-1"},{"issue":"4\u20136","key":"1112_CR84","first-page":"51","volume":"19","author":"C Magdalena","year":"2022","unstructured":"Magdalena C, Clarissa A, Sutandi N. Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder treated with rituximab, azathioprine, and mycophenolate mofetil: a systematic review and meta-analysis. Innov Clin Neurosci. 2022;19(4\u20136):51\u201364.","journal-title":"Innov Clin Neurosci"},{"key":"1112_CR85","doi-asserted-by":"crossref","unstructured":"Jacob A, Weinshenker BG, Violich I, McLinskey N, Krupp L, Fox RJ, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol. 2008;65(11):1443\u20138. (Treatment of NMO with rituximab).","DOI":"10.1001\/archneur.65.11.noc80069"},{"issue":"3","key":"1112_CR86","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/nrneurol.2011.1","volume":"7","author":"Bosch X, Saiz A, Ramos-Casals M, Group BS","year":"2011","unstructured":"Bosch X, Saiz A, Ramos-Casals M, Group BS. Monoclonal antibody therapy-associated neurological disorders. Nat Rev Neurol. 2011;7(3):165\u201372.","journal-title":"Nat Rev Neurol"}],"container-title":["Current Allergy and Asthma Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-023-01112-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11882-023-01112-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-023-01112-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T21:59:11Z","timestamp":1702418351000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11882-023-01112-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,27]]},"references-count":86,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["1112"],"URL":"https:\/\/doi.org\/10.1007\/s11882-023-01112-y","relation":{},"ISSN":["1529-7322","1534-6315"],"issn-type":[{"value":"1529-7322","type":"print"},{"value":"1534-6315","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,27]]},"assertion":[{"value":"18 October 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human and animal subjects performed by the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}